Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T18:05:10.232Z.
Calculation as of: 2026-10-06T18:05:10.232Z.
Quote observation: 2026-10-06T17:39:12.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 92121ceff5fa8810ba44f4cfbc32d43134c549094e5f0bfbc79a82dde622c70d
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
Revelation Biosciences, Inc.
Market Cap
$3.05M
Price/FCF Ratio
N/A
| NAME | MARKET CAP | PRICE/FCF RATIO |
|---|---|---|
| Revelation Biosciences, Inc. (REVB) | $3.05M | N/A |
| Adagio Medical Holdings, Inc. (ADGM)vs › | $3.04M | N/A |
| BioRestorative Therapies, Inc. (BRTX)vs › | $3.01M | N/A |
| IceCure Medical Ltd (ICCM)vs › | $3.11M | N/A |
| MBody AI Ltd. (MBAI)vs › | $3.16M | N/A |
| Paranovus Entertainment Technology Ltd. (PAVS)vs › | $3.28M | N/A |
| Universe Pharmaceuticals Inc. (UPC)vs › | $2.84M | N/A |
| Aethlon Medical, Inc. (AEMD)vs › | $3.22M | N/A |
| iSpecimen Inc. (ISPC)vs › | $2.77M | N/A |
| Moolec Science S.A. (MLEC)vs › | $3.46M | N/A |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
